<?xml version="1.0" ?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="-1"/>
	</teiHeader>
	<text xml:lang="en">
			<front>CORONAVIRUS <lb/>Seroprevalence of anti-SARS-CoV-2 IgG antibodies <lb/>in Kenyan blood donors <lb/>Sophie Uyoga 1 * †, Ifedayo M. O. Adetifa 1,2 †, Henry K. Karanja 1 †, James Nyagwange 1 †, James Tuju 1 , <lb/>Perpetual Wanjiku 1 , Rashid Aman 3 , Mercy Mwangangi 3 , Patrick Amoth 3 , Kadondi Kasera 3 , <lb/>Wangari Ng&apos;ang&apos;a 4 , Charles Rombo 5 , Christine Yegon 5 , Khamisi Kithi 5 , Elizabeth Odhiambo 5 , <lb/>Thomas Rotich 5 , Irene Orgut 5 , Sammy Kihara 5 , Mark Otiende 1 , Christian Bottomley 2 , Zonia N. Mupe 1 , <lb/>Eunice W. Kagucia 1 , Katherine E. Gallagher 1,2 , Anthony Etyang 1 , Shirine Voller 1,2 , John N. Gitonga 1 , <lb/>Daisy Mugo 1 , Charles N. Agoti 1 , Edward Otieno 1 , Leonard Ndwiga 1 , Teresa Lambe 6 , Daniel Wright 6 , <lb/>Edwine Barasa 1 , Benjamin Tsofa 1 , Philip Bejon 1,6 , Lynette I. Ochola-Oyier 1 , Ambrose Agweyu 1 ‡, <lb/>J. Anthony G. Scott 1,2 ‡, George M. Warimwe 1,6 ‡ <lb/>The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is poorly <lb/>described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020, and an overwhelming <lb/>number of cases and deaths were expected, but by 31 July 2020, there were only 20,636 cases and <lb/>341 deaths. However, the extent of SARS-CoV-2 exposure in the community remains unknown. We <lb/>determined the prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya <lb/>in April-June 2020. Crude seroprevalence was 5.6% (174 of 3098). Population-weighted, test-<lb/>performance-adjusted national seroprevalence was 4.3% (95% confidence interval, 2.9 to 5.8%) and <lb/>was highest in urban counties Mombasa (8.0%), Nairobi (7.3%), and Kisumu (5.5%). SARS-CoV-2 <lb/>exposure is more extensive than indicated by case-based surveillance, and these results will help guide <lb/>the pandemic response in Kenya and across Africa. <lb/></front>

			<body>A <lb/>frica accounts for 17% of the global pop-<lb/>ulation (1) but by late July 2020 accounted <lb/>for only 5% of the global COVID-19 cases <lb/>and 3% of global COVID-19 deaths re-<lb/>ported (2). This disparity has been at-<lb/>tributed to limited capacity for diagnosis, <lb/>timely implementation of stringent contain-<lb/>ment measures, a younger population struc-<lb/>ture, and a predominance of asymptomatic <lb/>and mild infections (3, 4). The first case of <lb/>COVID-19 in Kenya was detected on 12 March <lb/>2020. Within 1 week, the government insti-<lb/>tuted containment measures to limit the spread <lb/>of the virus (5). By 31 July national surveillance <lb/>recorded 20,636 cases and 341 deaths (6). This <lb/>increase in cases is notably slower than the <lb/>epidemic in Wuhan, Europe, or the United <lb/>States. Recently, it has been suggested that <lb/>&quot;the virus is spreading… …with an attenuated <lb/>outcome in Africa&quot; [(7), p. 626], but there are <lb/>few data available to confirm or refute this <lb/>assertion. <lb/>In countries affected early in the pandemic, <lb/>serological surveillance was used to define <lb/>cumulative incidence. For example, at the re-<lb/>lease of lockdown in Wuhan, 9.6% of staff <lb/>resuming work were found to have antibodies <lb/>to severe acute respiratory syndrome corona-<lb/>virus 2 (SARS-CoV-2) (8). At the end of the <lb/>epidemic wave in Spain, seropositivity was <lb/>5.0% in a random population sample of 60,897 <lb/>(9). As the epidemic curve declined in Geneva, <lb/>seroprevalence rose over 3 weeks from 4.8 to <lb/>10.9% (10). Currently, there are few estimates <lb/>of SARS-CoV-2 seroprevalence in Africa in the <lb/>literature (11). <lb/>Movement restrictions, in response to COVID-<lb/>19, have limited the conduct of fieldwork for <lb/>population-based serosurveys. Several coun-<lb/>tries have monitored seroprevalence in blood <lb/>transfusion donors (12, 13) or expectant moth-<lb/>ers attending antenatal clinics (14). Here, we <lb/>report the results of a pragmatic national sero-<lb/>survey using residual blood samples from <lb/>transfusion donors across Kenya and a highly <lb/>sensitive and specific assay for anti-SARS-<lb/>CoV-2 spike immunoglobulin G (IgG). <lb/>We validated a widely used enzyme-linked <lb/>immunosorbent assay (ELISA) for SARS-CoV-2 <lb/>IgG (15) with 910 serum samples from the pre-<lb/>pandemic period and 174 sera from polymer-<lb/>ase chain reaction (PCR)-defined SARS-CoV-2 <lb/>cases, and a well-characterized five-sera panel <lb/>from the National Institute of Biological Stan-<lb/>dards and Control (NIBSC) in the UK. For either <lb/>receptor-binding domain (RBD) or whole spike, <lb/>specificity was higher when using a ratio of <lb/>the sample optical density (OD)/negative con-<lb/>trol OD than when using the raw sample OD <lb/>plus 3 standard deviations to define seropo-<lb/>sitivity (table S1). By using OD ratios, both <lb/>RBD and spike ELISAs correctly classified <lb/>901 of 910 prepandemic samples as serone-<lb/>gative (table S1). However, the spike ELISA <lb/>detected more seropositives (166 of 179 com-<lb/>pared with 145 of 179 for RBD ELISA) among <lb/>sera from SARS-CoV-2 PCR-positive individu-<lb/>als (fig. S2, A and B). On the basis of these data, <lb/>we defined anti-SARS-CoV-2 IgG seropositiv-<lb/>ity as an OD ratio &gt;2 and selected the spike <lb/>ELISA for this study. The sensitivity and spe-<lb/>cificity, at this threshold, were 92.7% [95% <lb/>confidence interval (CI), 87.9 to 96.1%] and <lb/>99.0% [95% CI, 98.1 to 99.5%], respectively (figs. <lb/>S3, A and B, S5, and S6; and table S1). As pre-<lb/>viously noted (15), the RBD and whole-spike <lb/>ELISA responses were highly correlated (fig. S3C), <lb/>with very little interassay variation (fig. S4). <lb/>A total of 3174 blood transfusion samples <lb/>were collected from four Kenya National Blood <lb/>Transfusion Service (KNBTS) regional blood <lb/>transfusion centers that are supported by sev-<lb/>eral satellites and hospitals between 30 April <lb/>and 16 June 2020, from individuals aged 15 <lb/>to 66 years. Approximately half of the samples <lb/>were drawn in Mombasa; the remainder were <lb/>evenly distributed between Nairobi, Kisumu, <lb/>and Eldoret (Fig. 1 and table S2). We excluded <lb/>18 duplicate samples, 56 records missing data <lb/>on age or collection date, and two records <lb/>from individuals aged ≥65 years. Policy in <lb/>Kenya is to avoid blood donation from indi-<lb/>viduals &gt;65 years, and we excluded these other <lb/>data points as potentially unreliable. These <lb/>exclusions left 3098 samples for further anal-<lb/>ysis (Fig. 1). <lb/>Of the 3098 samples, 174 were positive for <lb/>anti-SARS-CoV-2 spike IgG, giving a crude <lb/>seroprevalence of 5.6% (95% CI, 4.8 to 6.5%). <lb/>Crude seroprevalence varied by age (P = 0.046), <lb/>ranging between 3.4 to 7.0% among adults <lb/>15 to 54 years; all 71 donors aged 55 to 64 years <lb/>were seronegative (Table 1). Crude seropre-<lb/>valence did not vary by sex (P = 0.50) but did <lb/>vary geographically, from 1.9% in the Rift <lb/>Valley region to 10.0% in the Western region <lb/>(P = 0.002) (Table 1). <lb/>Compared with the 2019 Kenya Population <lb/>and Housing Census, our participants were <lb/>more commonly male (82.0% in our study ver-<lb/>sus 49.3% in the census), had more persons <lb/>aged 25 to 34 years (40.1 versus 27.3%), and <lb/>more residents of coastal counties (49.2 versus <lb/>9.1%) (Table 2). We therefore adjusted the prev-<lb/>alence estimate for the demographics of the <lb/>sample using poststratification, and for the <lb/>sensitivity and specificity of the test. <lb/>The Bayesian population-weighted and test-<lb/>adjusted seroprevalence for Kenya was 4.3% <lb/>(95% CI, 2.9 to 5.8%) (Table 1), and the pos-<lb/>terior sensitivity and specificity estimates were <lb/>92.4% (95% CI, 88.0 to 95.6%) and 98.9 (95% <lb/>CI, 98.2 to 99.5%), respectively. Seroprevalence <lb/>was higher (4.2 to 5.2%) in the younger age <lb/>groups (15 to 44 years) and declined in the <lb/>older age groups (45 to 64 years) but was sim-<lb/>ilar for both sexes. Seroprevalence was highest <lb/>for those living in Mombasa, Nairobi, and the <lb/></body>

			<front>RESEARCH <lb/>Uyoga et al., Science 371, 79-82 (2021) <lb/>1 January 2021 <lb/>1 of 4 <lb/>1 KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. <lb/>2 <lb/>Department of Infectious Diseases Epidemiology, London <lb/>School of Hygiene and Tropical Medicine, Keppel Street, <lb/>London, UK. 3 Ministry of Health, Government of Kenya, Nairobi, <lb/>Kenya. 4 Presidential Policy and Strategy Unit, The Presidency, <lb/>Government of Kenya, Nairobi, Kenya. 5 Kenya National Blood <lb/>Transfusion Services, Ministry of Health, Nairobi, Kenya. <lb/>6 <lb/>Nuffield Department of Medicine, Oxford University, Oxford, UK. <lb/>*Corresponding author. Email: suyoga@kemri-wellcome.org <lb/> †These authors contributed equally to this work. ‡These authors <lb/>contributed equally to this work. <lb/></front>

			<body>Western region, although the number of ob-<lb/>servations for the Western region was small. <lb/>The directly standardized seroprevalence esti-<lb/>mates are presented in table S3. Seropreva-<lb/>lence was also calculated for counties that had <lb/>at least 120 donors sampled. The three largest <lb/>urban counties of Mombasa, Nairobi, and <lb/>Kisumu had SARS-CoV-2 seroprevalence of <lb/>8.0% (95% CI, 5.5 to 11.1%), 7.3% (95% CI, 4.2 <lb/>to 11.4%), and 5.5% (95% CI, 2.8 to 9.6%), re-<lb/>spectively (table S4). <lb/>The frequency of blood donor sampling and <lb/>crude seroprevalence estimates increased with <lb/>time over the 7-week study period (Fig. 2). The <lb/>median sample date was 30 May 2020, and the <lb/>midpoint of the study was 24 May 2020. We <lb/>did not adjust for sample date because the <lb/>period of sampling varied for residents of dif-<lb/>ferent counties (Fig. 2C); instead, we show the <lb/>variation in crude prevalence over time (Fig. 2A). <lb/>Voluntary nonremunerated donors (VNRDs), <lb/>who donate blood at community-based &quot;blood <lb/>drives,&quot; made up only 7.6% (236 of 3098) of <lb/>our sample of donors; the remainder were <lb/>family replacement donors (FRDs) who provide <lb/>a unit of blood in compensation for a transfu-<lb/>sion received by a sick relative. The two groups <lb/>did not differ significantly by age (P = 0.15) or <lb/>sex (P = 0.51) (table S5). Crude seroprevalence <lb/>was 8.5% (20 of 236) for VNRDs and 5.4% (154 <lb/>of 2862) for FRDs. The median sample date for <lb/>VNRDs (14 June 2020) was 2 weeks later than <lb/>that for FRDs (29 May 2020). <lb/>Population exposure across Kenya, with a <lb/>population-weighted test-adjusted seroprev-<lb/>alence of 4.3%, is considerably higher than <lb/>was previously thought, on the basis of the <lb/>cases and deaths reported to date. Seropreva-<lb/>lence was particularly high in the three urban <lb/>counties: Mombasa (8.0%), Nairobi (7.3%), and <lb/>Kisumu (5.5%). Consistent with other studies, <lb/>seroprevalence did not vary significantly by sex <lb/>(9, 10, 16); however, it peaked in 35-to 44-year-<lb/>olds and was lowest for those ≥45 years, which <lb/>is also consistent with existing reports in which <lb/>seroprevalence was found to be lower in older <lb/>adults (9, 10). <lb/>SARS-CoV-2 seroprevalence in our study is <lb/>comparable with estimates from large population-<lb/>based serosurveys in China, Switzerland, Spain, <lb/></body>

            <note place="footnote">Uyoga et al., Science 371, 79-82 (2021) <lb/>1 January 2021 <lb/></note>

            <page>2 of 4 <lb/></page>

            <body>Samples submitted by Kenya <lb/>National Blood Transfusion <lb/>Service Regional Centres <lb/>1575 (49.6%) Mombasa <lb/>600 (18.9%) Nairobi <lb/>499 (15.7%) Kisumu <lb/>500 (15.8%) Eldoret <lb/>3174 Total <lb/>Unique samples <lb/>3156 <lb/>Complete data <lb/>3100 <lb/>Age 15-64 years <lb/>3098 <lb/>Age &gt;64 years 2 <lb/>Missing collection date 12 <lb/>Missing age 44 <lb/>Duplicate samples 18 <lb/>Fig. 1. Participant flow diagram for SARS-CoV-2 <lb/>seroprevalence study of blood donors in <lb/>Kenya. Exclusion criteria for the selection of samples <lb/>with complete data. <lb/>0 <lb/>50 <lb/>100 <lb/>150 <lb/>200 <lb/>250 <lb/>Daily number of samples <lb/>Apr 30 <lb/>May 7 <lb/>May 14 <lb/>May 21 <lb/>May 28 <lb/>Jun 4 <lb/>Jun 11 <lb/>Jun 18 <lb/>Apr 30 <lb/>May 7 <lb/>May 14 <lb/>May 21 <lb/>May 28 <lb/>Jun 4 <lb/>Jun 11 <lb/>Jun 18 <lb/>Apr 30 <lb/>May 7 <lb/>May 14 <lb/>May 21 <lb/>May 28 <lb/>Jun 4 <lb/>Jun 11 <lb/>Jun 18 <lb/>Date <lb/>0 <lb/>4 <lb/>8 <lb/>12 <lb/>16 <lb/>Seroprevalence (%) <lb/>Western <lb/>Rift Valley <lb/>Nyanza <lb/>Nairobi <lb/>Eastern &amp; N. Eastern <lb/>Other Coast <lb/>Mombasa <lb/>Central <lb/>A <lb/>B <lb/>C <lb/>Fig. 2. Timeline of sampling for SARS-CoV-2 seroprevalence in blood donors in Kenya. (A to C) Against <lb/>the timeline of the sampling period, (A) is the weekly crude seroprevalence and 95% confidence interval, <lb/>(B) is the daily frequency of samples collected, and (C) is the temporal distribution of samples by region. Shown <lb/>are the proportion, counts, and regional distribution of donors during the study period. <lb/></body>

			<note place="headnote">RESEARCH | REPORT <lb/></note>

			<body>and the United States after the initial epidemic <lb/>peak and after many tens of thousands of <lb/>deaths (9, 10, 17, 18). Our results are also com-<lb/>parable with those of other surveys of blood <lb/>donors in Brazil (13), Italy (12), and many parts <lb/>of England (19). Kenya has an estimated popu-<lb/>lation of 53 million in 2020, and 57% of the <lb/>population is aged 15 to 64 years. If the trans-<lb/>fusion donor seroprevalence of 4.3% was ap-<lb/>plied to all 15-to 64-year-olds, it would suggest <lb/>approximately 1.3 million infections. However, <lb/>by the median sample date, 30 May 2020, only <lb/>2093 cases had been detected (of which ap-<lb/>proximately 90% were asymptomatic), and there <lb/>were 71 deaths among all ages (6). Although it <lb/>is difficult to extrapolate our data directly to <lb/>the whole population, they do strongly sug-<lb/>gest that the infection is more widespread <lb/>in Kenya than the current PCR test results <lb/>suggest and indicate a need for more sys-<lb/>tematic testing. The current PCR testing <lb/>strategy targets symptomatic individuals, <lb/>health care workers, contacts of confirmed <lb/>cases, international travelers, cross-border <lb/>truck drivers, and residents of areas identi-<lb/>fied as &quot;hotspots.&quot; <lb/>What are the potential explanations for the <lb/>divergence in the ratio of observed cases or <lb/>deaths to serologically defined infections in-<lb/>ferred from transfusion donors in Kenya, com-<lb/>pared with many high-income countries? (i) <lb/>The seroprevalence could be overestimated <lb/>because of bias in the selection or behavior <lb/>of blood transfusion donors. (ii) Cases could <lb/>be underascertained by national public health <lb/>surveillance, although it seems unlikely that <lb/>reporting of deaths and severe cases could be <lb/>reduced by several orders of magnitude, and <lb/>hospitals in Kenya were not overwhelmed by <lb/>admissions with respiratory illness. (iii) The <lb/>steep demographic age-pyramid results in a <lb/>smaller vulnerable age group. In Kenya, only <lb/>3.9% of the population is aged 65 years or <lb/>greater, which is substantially less than, for <lb/>example, 23.3% found in Italy; again, this <lb/>would only explain a moderate reduction <lb/>in severe cases or deaths (4). (iv) There may <lb/>be alternative mechanisms of immunity to <lb/>SARS-CoV-2, including cell-mediated immu-<lb/>nity (20, 21), perhaps as a result of human <lb/>coronavirus (HCoV)-elicited immunity (22, 23). <lb/>Despite our prior work showing that HCoVs <lb/>circulate in Kenya (24), we did not identify <lb/>evidence of cross-reactive antibodies to en-<lb/>demic coronaviruses in our validation study. <lb/>Although blood donors are not representa-<lb/>tive of the Kenyan population as a whole, we <lb/>adjusted for demographic bias in the sample <lb/>structure by standardization against the age, <lb/>sex, and regional distribution of the Kenyan <lb/>population. A substantial proportion (43%) of <lb/>the population of Kenya is outside the age <lb/>range (15 to 64 years) sampled in this study, <lb/>and the seroprevalence in children &lt;15 years <lb/>and adults &gt;65 years is often lower (9, 10); <lb/>our estimate for blood donors may be higher <lb/>than the estimate for the population as a <lb/>whole. Blood donors also differ from the gen-<lb/>eral population in their risk of exposure to <lb/>SARS-CoV-2. For example, potential donors <lb/>are excluded from giving blood if they have <lb/>been ill during the past 6 months, so the sam-<lb/>ple may underestimate the population prev-<lb/>alence of SARS-CoV-2 antibodies; however, <lb/>people who are shielding at home are unlikely <lb/>to be captured in our sample, leading to an <lb/>overestimate of seroprevalence. Our explora-<lb/>tion of the two distinct populations of blood <lb/>donors, FRDs and VNRDs, suggests variation <lb/>in the seroprevalence by donor group, but 92% <lb/>(2862 of 3098) of our sample came from the <lb/>group with lower seroprevalence, and exclu-<lb/>sion of VNRDs reduced little the crude sero-<lb/>prevalence in our study, from 5.6 to 5.4%. <lb/>Against these considerations, other coun-<lb/>tries have relied on blood transfusion donors <lb/>for an early estimate of seroprevalence, but <lb/>later estimates from random population sam-<lb/>ples have not been substantially different <lb/>(25, 26). <lb/></body>

			<note place="headnote">Uyoga et al., Science 371, 79-82 (2021) <lb/>1 January 2021 <lb/></note>

			<page>3 of 4 <lb/></page>

			<body>Table 1. Crude, population-weighted, and test performance-adjusted SARS-CoV-2 anti-spike protein IgG seroprevalence by participant characteris-<lb/>tics and regions. Prevalence estimates were calculated by using multilevel regression and poststratification (MLRP) to account for differences in the sample <lb/>population and the national population and subsequently adjusted for assay sensitivity and specificity. <lb/>All samples <lb/>Seropositive <lb/>samples <lb/>Crude <lb/>seroprevalence <lb/>Kenya <lb/>population <lb/>(2019 Census) <lb/>Bayesian <lb/>population-weighted <lb/>seroprevalence* <lb/>Bayesian <lb/>population-weighted, <lb/>test-adjusted <lb/>seroprevalence* <lb/>% <lb/>(95% CI) <lb/>% <lb/>(95% CI) <lb/>% <lb/>(95% CI) <lb/>Age <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>15 to 24 years <lb/>808 <lb/>49 <lb/>6.1 <lb/>4.5 to 7.9 <lb/>9,733,174 <lb/>5.1 <lb/>3.7 to 6.9 <lb/>4.4 <lb/>2.7 to 6.4 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>25 to 34 years <lb/>1242 <lb/>66 <lb/>5.3 <lb/>4.1 to 6.7 <lb/>7,424,967 <lb/>4.9 <lb/>3.6 to 6.4 <lb/>4.2 <lb/>2.8 to 6.0 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>35 to 44 years <lb/>714 <lb/>50 <lb/>7.0 <lb/>5.2 to 9.1 <lb/>4,909,191 <lb/>5.9 <lb/>4.3 to 8.1 <lb/>5.2 <lb/>3.3 to 7.7 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>45 to 54 years <lb/>263 <lb/>9 <lb/>3.4 <lb/>1.6 to 6.4 <lb/>3,094,771 <lb/>3.8 <lb/>1.9 to 6.0 <lb/>3.0 <lb/>1.1 to 5.4 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>55 to 64 years <lb/>71 <lb/>0 <lb/>0 <lb/>1,988,062 <lb/>3.4 <lb/>0.7 to 6.2 <lb/>2.9 <lb/>0.7 to 5.7 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Sex ............................................................................................................................................................................................................................................................................................................................................ <lb/>Male <lb/>2540 <lb/>146 <lb/>5.7 <lb/>4.9 to 6.7 <lb/>13,388,243 <lb/>4.4 <lb/>2.9 to 6.2 <lb/>3.6 <lb/>1.9 to 5.8 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Female <lb/>558 <lb/>28 <lb/>5.0 <lb/>3.4 to 7.2 <lb/>13,761,922 <lb/>5.5 <lb/>4.4 to 6.8 <lb/>4.8 <lb/>3.5 to 6.4 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Regions ............................................................................................................................................................................................................................................................................................................................................ <lb/>Central <lb/>105 <lb/>7 <lb/>6.7 <lb/>2.7 to 13.2 <lb/>3,452,213 <lb/>5.6 <lb/>2.9 to 10.0 <lb/>4.9 <lb/>1.9 to 9.7 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Mombasa <lb/>550 <lb/>51 <lb/>9.3 <lb/>7.0 to 12.0 <lb/>792,072 <lb/>8.3 <lb/>6.1 to 10.9 <lb/>7.8 <lb/>5.4 to 10.8 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Other Coast <lb/>973 <lb/>39 <lb/>4.0 <lb/>2.9 to 5.4 <lb/>1,671,097 <lb/>3.7 <lb/>2.6 v 5.1 <lb/>2.9 <lb/>1.6 to 4.6 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Eastern/N. Eastern <lb/>242 <lb/>11 <lb/>4.5 <lb/>2.3 to 8.0 <lb/>5,176,080 <lb/>4.3 <lb/>2.5 to 7.0 <lb/>3.5 <lb/>1.4 to 6.6 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Nairobi <lb/>235 <lb/>21 <lb/>8.9 <lb/>5.6 to 13.3 <lb/>3,002,314 <lb/>7.6 <lb/>4.9 to 11.2 <lb/>7.1 <lb/>4.2 to 11.2 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Nyanza <lb/>442 <lb/>30 <lb/>6.8 <lb/>4.6 to 9.5 <lb/>3,363,813 <lb/>6.0 <lb/>4.2 to 8.4 <lb/>5.2 <lb/>3.1 to 7.9 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Rift Valley <lb/>481 <lb/>8 <lb/>1.7 <lb/>0.7 to 3.3 <lb/>7,035,581 <lb/>2.1 <lb/>1.1 to 3.6 <lb/>1.5 <lb/>0.4 to 3.1 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Western <lb/>70 <lb/>7 <lb/>10.0 <lb/>4.1 to 19.5 <lb/>2,656,995 <lb/>7.0 <lb/>3.5 to 13.1 <lb/>6.3 <lb/>2.5 to 13.1 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>Total <lb/>3,098 <lb/>174 <lb/>5.6 <lb/>4.8 to 6.5 <lb/>27,150,165 <lb/>4.9 <lb/>3.9 to 6.2 <lb/>4.3 <lb/>2.9 to 5.8 <lb/>............................................................................................................................................................................................................................................................................................................................................ <lb/>*Reweighted prevalence estimates based on demographic data from the 2019 Kenya Population and Housing Census <lb/></body>

			<note place="headnote">RESEARCH | REPORT <lb/></note>

			<body>A key strength of this study is the rigorous <lb/>validation that included testing positive and <lb/>negative control samples from the target popu-<lb/>lation, as well as reference plasma from the UK <lb/>NIBSC as part of a World Health Organization <lb/>(WHO)-coordinated effort on SARS-CoV-2 sero-<lb/>epidemiology. In addition, we adopted a con-<lb/>servative seropositivity threshold to optimize <lb/>assay specificity and sensitivity for our setting. <lb/>The pandemic response in countries with <lb/>limited health care capacity has been driven <lb/>by the aggressive implementation of control <lb/>measures to limit transmission. Unfortunate-<lb/>ly, this strategy has been accompanied by <lb/>enormous collateral costs, particularly in <lb/>Africa. Modeled estimates of the disruptions of <lb/>essential medical services, such as immuniza-<lb/>tion and antenatal care, suggest an additional <lb/>~253,500 child deaths and 12,200 maternal <lb/>deaths over 6 months in low-and middle-<lb/>income countries (27). In the absence of social <lb/>protection, the economic effects of lockdown <lb/>are debilitating, so it is important to obtain an <lb/>early measure of the trajectory of the epidemic. <lb/>Our study provides a national and regional <lb/>estimate of population exposure to SARS-CoV-2 <lb/>in an African country. The 4.3% prevalence in <lb/>blood transfusion donors is in sharp contrast <lb/>with the reported COVID-19 cases and deaths <lb/>and supports the impression that disease may <lb/>be attenuated in Africa (7). <lb/></body>

			<listBibl>REFERENCES AND NOTES <lb/>1. United Nations Department of Economic and Social Affairs <lb/>Population Division, &quot;World Urbanization Prospects: The 2018 <lb/>Revision,&quot; custom data acquired via (2018); https:// <lb/>population.un.org/wup/DataQuery. <lb/>2. Africa Centres for Diseases Control and Prevention, <lb/>&quot;Coronavirus Disease 2019 (COVID-19)&quot; (2020); https:// <lb/>africacdc.org/covid-19 [accessed 21 July 2020]. <lb/>3. B. Z. Diop, M. Ngom, C. Pougué Biyong, J. N. Pougué Biyong, <lb/>BMJ Glob. Health 5, e002699 (2020). <lb/>4. J. B. Dowd et al., Proc. Natl. Acad. Sci. U.S.A. 117, 9696-9698 <lb/>(2020). <lb/>5. Ministry of Health Kenya, &quot;Press Statement on the update <lb/>of the coronavirus in the country and response measures&quot; (2020); <lb/>www.health.go.ke/wp-content/uploads/2020/03/Coronavirus-<lb/>Press-Statement-March-17-2020.pdf. <lb/>6. Ministry of Health Kenya, &quot;COVID-19 Situation Reports (SITREP)&quot; <lb/>(2020); www.health.go.ke/#1591180376422-52af4c1e-256b. <lb/>7. M. Mbow et al., Science 369, 624-626 (2020). <lb/>8. X. Wu, B. Fu, L. Chen, Y. Feng, J. Med. Virol. 92, 1795-1796 <lb/>(2020). <lb/>9. M. Pollán et al., Lancet 396, 535-544 (2020). <lb/>10. S. Stringhini et al., Lancet 396, 313-319 (2020). <lb/>11. M. G. Chibwana et al., Wellcome Open Res. 5, 199 (2020). <lb/>12. L. Valenti et al., SARS-CoV-2 seroprevalence trends in healthy <lb/>blood donors during the COVID-19 Milan outbreak. medRxiv <lb/>2020.2005.2011.20098442 [Preprint] 31 May 2020. <lb/>13. L. Amorim Filho et al., Rev. Saude Publica 54, 69 (2020). <lb/>14. D. D. Flannery et al., Sci. Immunol. 5, eabd5709 (2020). <lb/>15. F. Amanat et al., Nat. Med. 26, 1033-1036 (2020). <lb/>16. A. T. Huang et al., Nat. Commun. 11, 4704 (2020). <lb/>17. X. Xu et al., Nat. Med. 26, 1193-1195 (2020). <lb/>18. F. P. Havers et al., Seroprevalence of antibodies to SARS-CoV-2 in <lb/>10 sites in the United States, March 23-May 12, 2020. JAMA <lb/>Intern Med, 10.1001/jamainternmed.2020.4130 (2020). <lb/>19. Public Health England, &quot;Sero-prevalence epidemiology, England. in <lb/>Weekly Coronavirus Disease 2019 (COVID-19) Surveillance <lb/>Report 2020 Week 28&quot; (2020); https://assets.publishing.service. <lb/>gov.uk/government/uploads/system/uploads/attachment_data/ <lb/>file/899301/Weekly_COVID19_Surveillance_Report_week_28.pdf. <lb/>20. A. Grifoni et al., Cell 181, 1489-1501.e15 (2020). <lb/>21. N. Le Bert et al., Nature 584, 457-462 (2020). <lb/>22. A. Sette, S. Crotty, Nat. Rev. Immunol. 20, 457-458 <lb/>(2020). <lb/>23. K. W. Ng et al., Pre-existing and de novo humoral immunity to <lb/>SARS-CoV-2 in humans. bioRxiv 2020.2005.2014.095414 <lb/>[Preprint] 23 July 2020. <lb/>24. G. P. Otieno et al., Wellcome Open Res. 5, 150 (2020). <lb/>25. H. Ward et al., Antibody prevalence for SARS-CoV-2 following <lb/>the peak of the pandemic in England: REACT2 study in <lb/>100,000 adults. medRxiv 2020.2008.2012.20173690v20173692 <lb/>[Preprint] 21 August 2020. <lb/>26. Public Health England, National COVID-19 surveillance report <lb/>week 40 (2020); https://assets.publishing.service.gov.uk/ <lb/>government/uploads/system/uploads/attachment_data/file/ <lb/>923668/Weekly_COVID19_Surveillance_Report_week_40.pdf. <lb/>27. T. Roberton et al., Lancet Glob. Health 8, e901-e908 <lb/>(2020). <lb/>28. S. Uyoga et al., Replication Data for: Seroprevalence of <lb/>anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Harvard <lb/>Database (2020); https://doi.org/10.7910/DVN/RENVC9. <lb/></listBibl>

			<div type="acknowledgement">ACKNOWLEDGMENTS <lb/>We thank F. Krammer for providing the plasmids used to generate the <lb/>RBD, spike protein, and CR3022 monoclonal antibody used in this <lb/>work. Development of SARS-CoV-2 reagents was partially supported <lb/>by the NIAID Centres of Excellence for Influenza Research and <lb/>Surveillance (CEIRS) contract HHSN272201400008C. The COVID-19 <lb/>convalescent plasma panel (NIBSC 20/118) and research reagent <lb/>for SARS-CoV-2 Ab (NIBSC 20/130) were obtained from the NIBSC, <lb/>UK. We thank the blood donors and KNBTS staff who supported <lb/>this work. We also thank the WHO SOLIDARITY II network for sharing <lb/>of protocols and for facilitating the development and distribution of <lb/>control reagents. This paper has been published with the permission <lb/>of the director, Kenya Medical Research Institute. This study was <lb/>approved by the Scientific and Ethics Review Unit (SERU) of the <lb/>Kenya Medical Research Institute (Protocol SSC 3426). Before the <lb/>blood draw, donors gave individual consent for the use of their <lb/>samples for research. Ethical approval was obtained for collection, <lb/>storage, and further use for the sample sets used in the validation <lb/>assays (SERU numbers 1433, 3149, and 3426).</div>

            <div type="funding">Funding: This project <lb/>was funded by the Wellcome Trust (grants 220991/Z/20/Z and <lb/>203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-<lb/>017547), and the Foreign Commonwealth and Development Office <lb/>(FCDO) through the East Africa Research Fund (EARF/ITT/039). <lb/>S.U. is funded by DELTAS Africa Initiative [DEL-15-003], L.I.O.-O. <lb/>is funded by a Wellcome Trust Intermediate Fellowship <lb/>(107568/Z/15/Z), A.A. is funded by a DFID/MRC/NIHR/ <lb/>Wellcome Trust Joint Global Health Trials Award (MR/ <lb/>R006083/1), J.A.G.S. is funded by a Wellcome Trust Senior <lb/>Research Fellowship (214320) and the NIHR Health Protection <lb/>Research Unit in Immunisation, I.M.O.A. is funded by the United <lb/>Kingdom&apos;s Medical Research Council and Department For <lb/>International Development through an African Research Leader <lb/>Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL <lb/>(grant 2268427 LSHTM). G.M.W. is supported by a fellowship <lb/>from the Oak Foundation. C.N.A. is funded by the DELTAS Africa <lb/>Initiative [DEL-15-003], and the Department for International <lb/>Development and Wellcome (220985/Z/20/Z).</div>

            <div type="annex">Author <lb/>contributions: Conceptualization and methodology: S.U., I.M.O.A., <lb/>A.A., J.A.G.S., E.W.K., K.E.G., A.E., S.V., R.A., M.M., P.A., K.Ka., W.N., <lb/>and G.M.W. Investigation: S.U., H.K.K., J.N., J.T., P.W., C.R., C.Y., K.Ki., <lb/>E.Od., T.R., I.O., S.K., Z.N.M., J.N.G., D.M., C.N.A., E.Ot., L.N., L.I.O.-O., <lb/>and G.M.W. Formal analysis: J.A.G.S., M.O., and C.B. Validation: <lb/>T.L., D.W., H.K.K., J.N., J.T., L.I.O.-O., and G.M.W. Resources and <lb/>funding acquisition: S.U., T.L., P.B., and G.M.W. Supervision: E.B., <lb/>B.T., and P.B. Writing, original draft preparation: S.U., I.M.O.A., <lb/>A.A., J.A.G.S., and G.M.W. Writing, review and editing: all <lb/>authors.</div>

            <div type="annex">Competing interests: R.A., M.M., K.K., and P.A. are <lb/>from the Ministry of Health, Government of Kenya. All other <lb/>authors declare no competing interests.</div>

            <div type="availability">Data and materials <lb/>availability: Deidentified data has been published on the Havard <lb/>dataverse server (28).</div>

            <front>This work is licensed under a Creative <lb/>Commons Attribution 4.0 International (CC BY 4.0) license, which <lb/>permits unrestricted use, distribution, and reproduction in any <lb/>medium, provided the original work is properly cited. To view a copy <lb/>of this license, visit https://creativecommons.org/licenses/by/4.0/. <lb/>This license does not apply to figures/photos/artwork or <lb/>other content included in the article that is credited to a third <lb/>party; obtain authorization from the rights holder before using <lb/>such material.&quot; <lb/></front>

			<div type="annex">SUPPLEMENTARY MATERIALS <lb/>science.sciencemag.org/content/371/6524/79/suppl/DC1 <lb/>Materials and Methods <lb/>Figs. S1 to S6 <lb/>Tables S1 to S5 <lb/>References (29-32) <lb/>MDAR Reproducibility Checklist <lb/>View/request a protocol for this paper from Bio-protocol. <lb/>20 August 2020; accepted 6 November 2020 <lb/>Published online 11 November 2020 <lb/>10.1126/science.abe1916 <lb/></div>

			<note place="footnote">Uyoga et al., Science 371, 79-82 (2021) <lb/>1 January 2021 <lb/></note>

			<page>4 of 4 <lb/></page>

			<body>Table 2. General characteristics of the study population compared with the national popula-<lb/>tion of Kenya. N is the number of individuals in each stratum. <lb/>Blood transfusion samples <lb/>Kenya National Census 2019 <lb/>N <lb/>% <lb/>N <lb/>% <lb/>Age <lb/>15 to 24 years <lb/>808 <lb/>26.1 <lb/>9,733,174 <lb/>35.8 <lb/>..................................................................................................................................................................................................................... <lb/>25 to 34 years <lb/>1,242 <lb/>40.1 <lb/>7,424,967 <lb/>27.3 <lb/>..................................................................................................................................................................................................................... <lb/>35 to 44 years <lb/>714 <lb/>23.0 <lb/>4,909,191 <lb/>18.1 <lb/>..................................................................................................................................................................................................................... <lb/>45 to 54 years <lb/>263 <lb/>8.5 <lb/>3,094,771 <lb/>11.4 <lb/>..................................................................................................................................................................................................................... <lb/>55 to 64 years <lb/>71 <lb/>2.3 <lb/>1,988,062 <lb/>7.3 <lb/>..................................................................................................................................................................................................................... <lb/>Sex <lb/>Male <lb/>2540 <lb/>82.0 <lb/>13,388,243 <lb/>49.3 <lb/>..................................................................................................................................................................................................................... <lb/>Female <lb/>558 <lb/>18.0 <lb/>13,761,922 <lb/>50.7 <lb/>..................................................................................................................................................................................................................... <lb/>Regions <lb/>Central <lb/>105 <lb/>3.4 <lb/>3,452,213 <lb/>12.7 <lb/>..................................................................................................................................................................................................................... <lb/>Mombasa <lb/>550 <lb/>17.8 <lb/>792,072 <lb/>2.9 <lb/>..................................................................................................................................................................................................................... <lb/>Other Coast <lb/>973 <lb/>31.4 <lb/>1,671,097 <lb/>6.2 <lb/>..................................................................................................................................................................................................................... <lb/>Eastern/Northeastern <lb/>242 <lb/>7.8 <lb/>5,176,080 <lb/>19.1 <lb/>..................................................................................................................................................................................................................... <lb/>Nairobi <lb/>235 <lb/>7.6 <lb/>3,002,314 <lb/>11.1 <lb/>..................................................................................................................................................................................................................... <lb/>Nyanza <lb/>442 <lb/>14.3 <lb/>3,363,813 <lb/>12.4 <lb/>..................................................................................................................................................................................................................... <lb/>Rift Valley <lb/>481 <lb/>15.5 <lb/>7,035,581 <lb/>25.9 <lb/>..................................................................................................................................................................................................................... <lb/>Western <lb/>70 <lb/>2.3 <lb/>2,656,995 <lb/>9.8 <lb/>..................................................................................................................................................................................................................... <lb/>Total <lb/>Kenya 15 to 64 years <lb/>3098 <lb/>27,150,165 <lb/>..................................................................................................................................................................................................................... <lb/></body>

			<note place="headnote">RESEARCH | REPORT </note>


	</text>
</tei>
